From multidrug-resistant tuberculosis to DOTS expansion and beyond: making the most of a paradigm shift.
This review examines the paradigm shift around multidrug-resistant tuberculosis (MDR-TB). This shift has centered largely on the activities of institutions participating in the World Health Organization's Working Group on DOTS-Plus for MDR-TB. We review the important milestones since 1995, namely, the emergence of new evidence, the construction of new mechanisms, and the building of consensus to support new policy guidelines. This paper offers a case study of the construction of a model of good global governance that--if the opportunity is taken--can improve access to effective TB care through improving and helping to expand the WHO-recommended DOTS strategy.
Kim
Jim Yong
JY
Program in Infectious Disease and Social Change, Department of Social Medicine, Harvard Medical School, 641 Huntington Avenue, Boston, MA 02115, USA. jim_yong_kim@hms.harvard.edu
Mukherjee
Joia S
JS
Rich
Michael L
ML
Mate
Kedar
K
Bayona
Jaime
J
Becerra
Mercedes C
MC
D000995:Antitubercular Agents / Q000627:therapeutic use*; D023801:Directly Observed Therapy / Q000639:trends*; D019317:Evidence-Based Medicine; D006801:Humans; D007391:International Cooperation; D017410:Practice Guidelines as Topic; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy*; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*
D000995:Antitubercular Agents